Pregnancy and breast feeding mother;
Estimated life expectancy <12 months;
Scheduled major surgery in the next 6 months;
Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk;
Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 30 days.
WHO group II, III, IV, V PH
Severe Renal dysfunction (Ccr<30 ml/min)
Blood platelet count<100,000/L
Expected life span<6-month
Systematical inflammation
Malignant cancer(s)
Tricuspid valve stenosis, Supra-pulmonary valve stenosis
Allergic to studied drugs or metal materials.

NCT02284737_exc_T1
Condition
Pregnancy
NCT02284737_exc_T2
Observation
breast feeding
NCT02284737_exc_T3
Observation
Estimated life expectancy
NCT02284737_exc_T4
Value
<12 months
NCT02284737_exc_T5
Mood
Scheduled
NCT02284737_exc_T6
Procedure
major surgery
NCT02284737_exc_T7
Temporal
in the next 6 months
NCT02284737_exc_T10
Measurement
WHO
NCT02284737_exc_T11
Value
group II, III, IV, V
NCT02284737_exc_T12
Condition
PH
NCT02284737_exc_T13
Condition
Renal dysfunction
NCT02284737_exc_T14
Qualifier
Severe
NCT02284737_exc_T15
Measurement
Ccr
NCT02284737_exc_T16
Value
<30 ml/min
NCT02284737_exc_T17
Scope
Severe Renal dysfunction
NCT02284737_exc_T18
Measurement
Blood platelet count
NCT02284737_exc_T19
Value
<100,000/L
NCT02284737_exc_T20
Observation
Expected life span
NCT02284737_exc_T21
Value
<6-month
NCT02284737_exc_T22
Condition
Systematical inflammation
NCT02284737_exc_T23
Condition
Malignant cancer
NCT02284737_exc_T24
Condition
Tricuspid valve stenosis
NCT02284737_exc_T25
Condition
Supra-pulmonary valve stenosis
NCT02284737_exc_T26
Condition
Allergic
NCT02284737_exc_T27
Drug
studied drugs
NCT02284737_exc_T28
Drug
s or me als.
NCT02284737_exc_T29
Scope
studied drugs or metal materials
NCT02284737_exc_T9
Temporal
Previous
NCT02284737_exc_T30
Procedure
treatment with an investigational drug
NCT02284737_exc_T31
Drug
investigational drug
NCT02284737_exc_T32
Observation
enrolment in this study
NCT02284737_exc_T33
Device
device
NCT02284737_exc_T8
Observation
Inability to follow the protocol
NCT02284737_exc_T34
Observation
bility to fo ply with follow-up requirements or